• Redx Bolsters Gastroenterology Expertise with Appointment of Chief Medical Officer

    Read more
  • Redx Announces Close of Series A Financing of $36 Million and Strengthened Board Composition

    Read more
  • Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

    Read more
  • RXC008 Receives US FDA Fast Track Designation

    Read more
  • US FDA lifts Partial Clinical Hold on Zelasudil

    Read more
  • Redx Pharma – Update to Year End

    Read more
  • Redx presents encouraging signal searching data for zelasudil (RXC007) as a well-tolerated treatment for Idiopathic Pulmonary Fibrosis at ERS

    Read more
  • Redx Pharma to present new Phase 2a data for zelasudil (RXC007) at ERS

    Read more
  • Redx presents Phase 1 data supporting RXC008 at DDW 2025

    Read more
  • Redx Pharma Concludes Trading on JP Jenkins

    Read more